Results 131 to 140 of about 288,727 (306)

FASLG Derived from Fibroblasts in Hydroxyapatite‐Rich Microenvironment Induces Urothelial Anoikis to Trigger Randall's Plaque Exposure

Advanced Science, EarlyView.
Randall's plaques (RP) serve as the nidus for calcium oxalate (CaOx) kidney stones. The current study reveals that hydroxyapatite (HAP) crystals activate the THY1–GSK3α/β–β‐catenin axis in renal interstitial fibroblasts (hRIFs), inducing FASLG secretion.
Minghui Liu, Maolan Wu, Meng Gao, Yongchao Li, Miao Yuan, Zhangcheng Liao, Zhi Liu, Yizhou Wang, Yu Cui, Jinbo Chen, Cheng He, Zhiyong Chen, Feng Zeng, Hequn Chen, Zewu Zhu   +14 more
wiley   +1 more source

Enhancing CAR‐T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF‐Mediated Angiogenesis

Advanced Science, EarlyView.
This study reveals that CAR‐T cells in solid tumors produce CCL5, which paradoxically induces VEGF and angiogenesis to promote tumor growth. Blocking CCL5/VEGF signaling—through gene knockout, or the CCR5 inhibitor maraviroc—significantly enhances the antitumor efficacy of CAR‑T therapy (the diagram was created in Biorender).
Shishuo Sun, Qihong Li, Bixi Wang, Gang Wang, Ying Xue, Yibing Liang, Chenhe Hu, Zhenyu Wang, Xiaoge Gao, Haiheng Xu, Jun Song, Hailong Li, Liantao Li, Xiaoxiao Liu, Patrick Ming‐Kuen Tang, Qing Zhang   +15 more
wiley   +1 more source

Inhibition of purine nucleoside and nucleobase transporters by tyrosine kinase inhibitors. [PDF]

PLoS One
Shahid N, Kim CH, Jabilona KB, Nguyen KH, Ruel NM, Hammond JR.   +5 more
europepmc   +1 more source

Tyrosine kinase inhibitors [PDF]

Cancer Cell, 2004
Arteaga, Carlos L., Baselga, Jose
openaire   +1 more source

A Circuit of Mechanically Regulated Transcription Factors Balances Regenerative and Fibrotic Memory of Mesenchymal Stromal Cells

Advanced Science, EarlyView.
Producing MSCs on rigid culture substrates induces a scar‐making phenotype, jeapordizing therapeutic success. ‘Tissue‐soft’ surfaces prevent MSC fibrogenesis and preserve regenerative traits. An epigenetic network, driven by HOXA11 and SALL1, maintains ‘soft memory’ by keeping chromatin open in relaxed MSCs, promoting anti‐fibrotic programs.
Fereshteh Sadat Younesi, Andrew E. Miller, Li Diao, Xinying Guo, Natalie Andonian, Elham Karimizadeh, Thomas H. Barker, Boris Hinz   +7 more
wiley   +1 more source

In Silico Studies of Potent Tyrosine Kinase Inhibitors: Molecular Docking and Pharmacophore Modeling Approaches. [PDF]

Molecules
Mavridis E, Pontiki E, Hadjipavlou-Litina D.   +2 more
europepmc   +1 more source

Challenges with Bruton’s Tyrosine Kinase Inhibitors Treatment [PDF]

Nahla A M Hamed
openalex   +1 more source

Aptamer‐Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer

Advanced Science, EarlyView.
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang, Xuan Wang, Xinfeng Dai, Linxin Tian, Wencheng Shen, Xueliang Liu, Wei Xue, Jiahua Pan, Yu Yang   +8 more
wiley   +1 more source

Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis: Mechanistic Considerations Across Relapsing and Progressive Disease. [PDF]

Molecules
Ye Q, Ma S.
europepmc   +1 more source

Alpha-fetoprotein response predicts treatment outcomes in patients with unresectable hepatocellular carcinoma receiving immune checkpoint inhibitors with or without tyrosine kinase inhibitors or locoregional therapies.

, 2021
Wei‐Fan Hsu, Hung‐Wei Wang, Cheng‐Kuo Chen, Hung‐Chun Lai, Po‐Heng Chuang, Ming-Hung Tsai, Wen‐Pang Su, Hung‐Yao Chen, Chia‐Sheng Chu, Jen‐Wei Chou, Sheng‐Hung Chen, Tsung-Yu Tsai, Wang‐De Hsiao, Chun-Che Lin, Guan‐Tarn Huang, Jaw-Town Lin, Cheng‐Yuan Peng   +16 more
openalex   +1 more source